RGMA抗体;RGMA Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of RGMA expression in Hela cell lysate.    

  
  

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

RGMA (Repulsive Guidance Molecule A) is a glycosylphosphatidylinositol (GPI)-anchored protein initially identified for its role in axon guidance during neural development. It functions as a repulsive cue by binding to its receptor Neogenin, modulating processes like neuronal migration, growth cone collapse, and synaptic plasticity. Beyond the nervous system, RGMA is implicated in immune regulation and cancer progression. Studies reveal its overexpression in tumors, where it contributes to immunosuppression by promoting T-cell exhaustion and recruiting immunosuppressive myeloid cells. This has positioned RGMA as a potential therapeutic target, particularly in cancers resistant to existing immunotherapies.

RGMA antibodies are designed to block its interaction with Neogenin or other ligands (e.g., bone morphogenetic proteins), aiming to neutralize its inhibitory effects. Preclinical models demonstrate that anti-RGMA antibodies enhance axon regeneration in spinal cord injury and restore antitumor immunity by reversing immune evasion mechanisms. Recent efforts focus on humanized antibodies for clinical translation, with studies exploring synergy with checkpoint inhibitors like anti-PD-1. Challenges include optimizing target specificity and managing potential off-target effects in neural tissues. Overall, RGMA antibodies represent a promising dual-directional strategy for both neuroregeneration and cancer immunotherapy.